Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial


The CSV-1000 Diagnostic Instrument is Considered the Standard of Care for the Measurement of Contrast Sensitivity

San Diego, CA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced that its standardized vision testing instrument, the CSV-1000, has been selected by the Foundation Fighting Blindness for inclusion in a large-scale multi-center long-term clinical trial, the PRO-EYS Study. This study is being conducted to evaluate vision loss and progression in patients with degenerative retinal disease. There are expected to be about 30 sites in the study, with each site having a dedicated CSV-1000 device. The CSV-1000 is manufactured by Guardion’s VectorVision subsidiary.

The mission of the Foundation Fighting Blindness is to fund research that will lead to the prevention, treatment and cure for the entire spectrum of retinal degenerative diseases. The Foundation Fighting Blindness is the largest-non-governmental source of research funds for inherited retinal degenerative diseases, having raised nearly $800 million over the past 48 years in support of its mission, and having initiated 36 clinical trials for potential treatments linked to retinal diseases.

Dr David Evans, Guardion’s Chief Science Officer and the founder of VectorVision, commenting on the selection of the CSV-1000 device for this study, stated: “The Foundation Fighting Blindness is doing important work in developing an understanding of vision loss in patients with degenerative retinal disease. We are pleased and honored to have our technology selected by the Foundation Fighting Blindness for use in this clinical trial.”

About Guardion Health Sciences, Inc.

Guardion is an ocular health sciences company that develops, formulates and distributes condition-specific medical foods supported by evidence-based protocols, with a lead medical food product, Lumega-Z®, that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, thereby providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the Securities and Exchange Commission (“SEC”) at

About VectorVision®

VectorVision®, operating through a wholly-owned subsidiary of the Company, specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website ( The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:Investor Relations Contact:
Michael FavishMatthew Abenante
Chief Executive OfficerPorter, LeVay & Rose, Inc.
Telephone: (858) 605-9055 x 201Telephone: (212) 564-4700
E-mail: mfavish@guardionhealth.comE-mail: